RPS6KB1 and neoplasm: The resultant increase in activated S6K1 can directly activate the estrogen receptor (ER) to increase transcription of ER-responsive genes independently of estrogen signaling, thereby rendering tumor cells unresponsive to endocrine therapy (Yamnik et al., 2009).